Agios Pharmaceuticals Inc (AGIO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.14 is considered Undervalued compared with the five-year average of -1.74. The fair price of Agios Pharmaceuticals Inc (AGIO) is between 34.87 to 53.55 according to relative valuation method. Compared to the current price of 29.05 USD , Agios Pharmaceuticals Inc By Undervalued By 16.7%.

Relative Value

Fair Zone

34.87-53.55

Current Price：29.05

16.7%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Agios Pharmaceuticals Inc (AGIO) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Agios Pharmaceuticals Inc (AGIO) has a current Price-to-Book (P/B) ratio of 1.23. Compared to its 3-year average P/B ratio of 1.85, the current P/B ratio is approximately -33.47% higher. Relative to its 5-year average P/B ratio of 1.80, the current P/B ratio is about -31.65% higher. Agios Pharmaceuticals Inc (AGIO) has a Forward Free Cash Flow (FCF) yield of approximately -26.13%. Compared to its 3-year average FCF yield of -19.04%, the current FCF yield is approximately 37.21% lower. Relative to its 5-year average FCF yield of -19.28%, the current FCF yield is about 35.48% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for AGIO competitors is 9.66, providing a benchmark for relative valuation. Agios Pharmaceuticals Inc Corp (AGIO.O) exhibits a P/S ratio of 20.14, which is 108.43% above the industry average. Given its robust revenue growth of 86.09%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of AGIO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of AGIO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is AGIO currently overvalued or undervalued?

Agios Pharmaceuticals Inc (AGIO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.14 is considered Undervalued compared with the five-year average of -1.74. The fair price of Agios Pharmaceuticals Inc (AGIO) is between 34.87 to 53.55 according to relative valuation method. Compared to the current price of 29.05 USD, Agios Pharmaceuticals Inc is Undervalued By 16.70%.

What is Agios Pharmaceuticals Inc (AGIO) fair value?

AGIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Agios Pharmaceuticals Inc (AGIO) is between 34.87 to 53.55 according to relative valuation method.

How does AGIO's valuation metrics compare to the industry average?

The average P/S ratio for AGIO's competitors is 9.66, providing a benchmark for relative valuation. Agios Pharmaceuticals Inc Corp (AGIO) exhibits a P/S ratio of 20.14, which is 108.43% above the industry average. Given its robust revenue growth of 86.09%, this premium appears sustainable.

What is the current P/B ratio for Agios Pharmaceuticals Inc (AGIO) as of Mar 02 2026?

As of Mar 02 2026, Agios Pharmaceuticals Inc (AGIO) has a P/B ratio of 1.23. This indicates that the market values AGIO at 1.23 times its book value.

What is the current FCF Yield for Agios Pharmaceuticals Inc (AGIO) as of Mar 02 2026?

As of Mar 02 2026, Agios Pharmaceuticals Inc (AGIO) has a FCF Yield of -26.13%. This means that for every dollar of Agios Pharmaceuticals Inc's market capitalization, the company generates -26.13 cents in free cash flow.

What is the current Forward P/E ratio for Agios Pharmaceuticals Inc (AGIO) as of Mar 02 2026?

As of Mar 02 2026, Agios Pharmaceuticals Inc (AGIO) has a Forward P/E ratio of -3.73. This means the market is willing to pay $-3.73 for every dollar of Agios Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Agios Pharmaceuticals Inc (AGIO) as of Mar 02 2026?

As of Mar 02 2026, Agios Pharmaceuticals Inc (AGIO) has a Forward P/S ratio of 20.14. This means the market is valuing AGIO at $20.14 for every dollar of expected revenue over the next 12 months.

AGIO Valuation